← The Wire
AMGNNasdaq
AMGEN INC
Biological Products, (No Diagnostic Substances) · DE · CIK 318154
AMGEN INC is a biopharmaceutical company
red 8-K · 90d🔥 High media attention
$191.70B
Market cap
$360.55
Last close
+0.6%
1D
+4.6%
5D
2.5M
Volume
Price · last 39 sessions+11.3%
May 4L $323.85 · H $360.55Jun 29
191
Total filings
Jun 11, 2026
Last filing
12/31
Fiscal year end
11-K11-KJun 11, 202611-K11-KJun 11, 20268-KShareholder VoteMay 20, 20268-KExecutive ChangeMay 19, 202610-Q10-QMay 1, 20268-KResults of OperationsApr 30, 20268-KExecutive ChangeApr 22, 2026DEFA14ADEFA14AApr 21, 2026DEFA14ADEFA14AApr 15, 2026DEFA14ADEFA14AApr 7, 2026DEF 14ADEF 14AApr 7, 20268-KMaterial AgreementFeb 19, 202610-K10-KFeb 13, 20268-KResults of OperationsFeb 3, 20268-KAgreement TerminatedJan 30, 202610-Q10-QNov 5, 20258-KResults of OperationsNov 4, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 5, 202511-K11-KJun 12, 202511-K11-KJun 12, 20258-KShareholder VoteMay 27, 202510-Q10-QMay 2, 20258-KResults of OperationsMay 1, 2025DEFA14ADEFA14AApr 29, 2025DEFA14ADEFA14AApr 17, 2025DEFA14ADEFA14AApr 9, 2025DEF 14ADEF 14AApr 9, 202510-K10-KFeb 14, 20258-KResults of OperationsFeb 4, 202510-Q10-QOct 31, 20248-KResults of OperationsOct 30, 202410-Q10-QAug 7, 20248-KResults of OperationsAug 6, 202411-K2023 PUERTO RICO PLAN 11-KJun 21, 202411-K2023 U.S. PLAN 11-KJun 21, 20248-KExecutive Change · Shareholder VoteJun 3, 2024DEFA14ADEFA14AMay 10, 2024DEFA14ADEFA14AMay 3, 202410-Q10-QMay 3, 20248-KResults of OperationsMay 2, 2024DEFA14ADEFA14AApr 26, 2024DEFA14ADEFA14AApr 17, 2024DEF 14ADEF 14AApr 17, 202410-K10-KFeb 14, 20248-KResults of OperationsFeb 6, 20248-KExecutive ChangeDec 14, 202310-Q10-QOct 31, 20238-KResults of OperationsOct 31, 20238-KAcquisition / Disposition · New Debt / ObligationOct 6, 20238-KCompany UpdateOct 5, 2023SC 13DSC 13DSep 27, 20238-KCompany UpdateSep 12, 20238-KCompany UpdateSep 5, 20238-KReg FD Disclosure · Company UpdateSep 1, 202310-Q10-QAug 4, 20238-KExecutive ChangeAug 4, 20238-KResults of OperationsAug 3, 202311-K2022 PUERTO RICO PLAN 11-KJun 15, 202311-K2022 U.S. PLAN 11-KJun 15, 20238-KCompany UpdateJun 5, 20238-KShareholder VoteMay 22, 20238-KCompany UpdateMay 18, 20238-KReg FD DisclosureMay 16, 2023DEFA14ADEFA14AMay 3, 202310-Q10-QApr 28, 20238-KResults of OperationsApr 27, 2023DEFA14ADEFA14AApr 25, 2023DEFA14ADEFA14AApr 14, 2023DEFA14ADEFA14AApr 6, 2023DEF 14ADEF 14AApr 6, 20238-KMaterial Agreement · Agreement TerminatedMar 9, 20238-KMaterial AgreementMar 2, 20238-KMaterial AgreementFeb 16, 202310-K10-KFeb 9, 20238-KMaterial Agreement · Results of OperationsJan 31, 20238-KMaterial Agreement · New Debt / ObligationDec 22, 20228-KMaterial Agreement · New Debt / ObligationDec 12, 20228-KReg FD DisclosureDec 2, 2022SC 13GSC 13GDec 2, 2022
Insider Activity
In the 90 days to Feb 26, 2026: 2 sold $21.1M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 26, 2026 | Santos EstebanEVP, Operations | Sell | 30,501 | $379.12 | $11.6M |
| Feb 26, 2026 | Santos EstebanEVP, Operations | Sell | 24,291 | $379.12 | $9.2M |
| Feb 19, 2026 | Busch Matthew C.VP, Finance & CAO | Sell | 1,000 | $375.79 | $376K |
| Nov 20, 2025 | Grygiel Nancy A.SVP & CCO | Sell | 1,639 | $337.26 | $553K |
| Nov 20, 2025 | Grygiel Nancy A.SVP & CCO | Sell | 1,500 | $337.26 | $506K |
| Nov 12, 2025 | Gordon MurdoEVP, Global Commercial Ops | Sell | 6,879 | $336.83 | $2.3M |
| Nov 12, 2025 | Khosla RachnaSVP, Business Development | Sell | 890 | $336.24 | $299K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
What Changed
Risk factors · Feb 14, 2025 → Feb 13, 2026113 added · 118 removed between the two most recent 10-Ks. The risks a company starts — or stops — disclosing are often the story.
Newly disclosed
- For example, the IRA includes provisions requiring mandatory pricing in Medicare for certain drugs under Parts B and D (starting with 10 drugs effective January 1, 2026, adding 15 in 2027 and 2028, and adding 20 in 2029 and subsequent years such that, by 2031, approximately 100 drugs would be subject to such set prices).
- The Colorado PDAB deemed three of five drugs “unaffordable,” including ENBREL, and in October 2025 the Colorado PDAB established an Upper Payment Limit (UPL) substantially lower than the wholesale acquisition cost of ENBREL that would be generally applicable to all formulations of ENBREL, effective no earlier than January 1, 2027, and will be reviewed annually.
- In November 2025, a third-party service provider had a cybersecurity incident in which Amgen-related information was accessed and disclosed by a threat actor that, upon review, did not involve information material to the Company.
- On January 5, 2026, the OECD issued additional administrative guidance related to the global minimum tax agreement that exempts U.S. companies from extra territorial minimum taxes effective January 1, 2026.
- While we have incorporated the impact of OB3 in our 2025 financial statements, the legislation is complex and guidance could be issued that could impact our 2025 or future U.S. taxes.
- For example, in the past we have experienced cybersecurity incidents involving third-party service providers, including incidents in which unauthorized third parties accessed or exfiltrated certain information, including non-significant Amgen data and personally identifiable patient information, and we 37 have made required regulatory notifications in connection with certain such incidents.
- For example, we have experienced cybersecurity incidents at third-party vendors that provide testing, analytical, information technology and clinical data services, which required us to temporarily disconnect our systems from those vendors.
- For example, we have previously experienced incidents in which third-party vendors initially reported that cyberattacks did not involve our data but later determined that attackers had accessed limited, non-significant Amgen information.
- For example, the Congressional Budget Office has projected that the OB3 will result in significant reductions in federal Medicaid spending over the next decade and an increase in the number of people without health insurance.
- Certain appellate courts have issued decisions both upholding certain state 340B statues and affirming the denial of preliminary injunctive relief to manufacturers, while litigation and appeals concerning the validity, interpretation, and enforcement of these laws remain ongoing.
- Delays, modifications or repeal, in whole or in part, of the administrative guidance or the OECD agreement itself, either by all OECD participants or unilaterally by individual countries, could result in negative impacts on our overall tax rate.
- Such attacks include the use of harmful and virulent malware, including ransomware or other denials of service, which can be deployed through various means, including the software supply chain, e-mail, malicious websites and/or the use of social engineering/phishing, and/or AI to orchestrate and automate sophisticated cyberattacks, including the documented instance in which an AI agent was used to conduct a large-scale intrusion campaign, potentially lowering the barriers to high-speed, high-volume attacks.
No longer disclosed
- For example, in the first half of 2021, a supplier experienced a data breach in which an unauthorized third party acquired access to certain information provided to the supplier in the course of its provision of services to us, including business documents and certain personally identifiable patient information (not including social security or other financial or health insurance information).
- For example, the IRA includes provisions requiring that, beginning in 2026, mandatory price setting be introduced in Medicare for certain drugs paid for under Parts B and D, whereby manufacturers must accept a price established by the government or face penalties on all U.S. sales (starting with 10 drugs in 2026, adding 15 in 2027 and 2028, and adding 20 in 2029 and subsequent 29 years such that, by 2031, approximately 100 drugs could be subject to such set prices).
- In 2022, Okta, Inc., a provider of software that helps companies manage user authentication, disclosed that several hundred of its corporate customers were vulnerable to a security breach that allowed attackers to access Okta’s internal network.
- In the third quarter of 2022, another service provider experienced a 36 similar cybersecurity breach in which an attacker exfiltrated certain data (including non-significant Amgen data) from the service provider’s systems.
- For example, in the United States, the FTC’s interim report released in 2024 showed that the top six integrated health plans and PBMs controlled about 94% of all pharmacy prescriptions.
- For example, in 2022, several Medicare Administrative Contractors issued notice that TEZSPIRE would be added to their “self-administered drug” exclusion lists.
- Court of Appeals for the 8th Circuit ruled that Arkansas’ Act 1103, which prohibits drugmakers from restricting the acquisition or delivery of 340B drugs to covered entities and their contract pharmacies, was not preempted by the federal 340B statute.
- For example, in September 2024, the FTC brought action against the three largest PBMs alleging anticompetitive and unfair rebating practices.
- For example, Horizon adds more than 30 contract manufacturing organizations (CMOs) to our operations, many of which are single source suppliers (including the CMO that produces TEPEZZA drug substance and the CMO that produces all of our KRYSTEXXA drug substance in Israel that is affected by the current conflict in Israel and Gaza).
- For example, some payers require physicians to demonstrate or document that the patients for whom Repatha has been prescribed meet their utilization criteria, and these requirements have served to limit patient access to Repatha treatment.
- Additional provisions of the OECD agreement may come into effect in future years, and the OECD is expected to continue to release additional guidance that may impact the application and interpretation of the agreement that could further increase our tax liabilities.
- We may not realize the anticipated strategic benefits of our acquisition of Horizon, including our efforts to leverage Amgen’s global presence and commercial and medical capabilities in inflammation and nephrology to accelerate revenue growth of Horizon’s products.
In the News
🔥 High media attentionCoverage (30d): 10 reputable articles · skews ▼ negative.
MarketWatchAmgen Inc. stock underperforms Friday when compared to competitors despite daily gains3d agoMarketWatchAmgen Inc. stock underperforms Wednesday when compared to competitors12d agoMarketWatchAmgen Inc. stock outperforms competitors despite losses on the day14d agoMarketWatchAmgen Inc. stock underperforms Monday when compared to competitors21d agoMarketWatchAmgen Inc. stock underperforms Thursday when compared to competitors despite daily gains25d agoMarketWatchAmgen Inc. stock outperforms competitors on strong trading day26d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance